ReviewFrontiers in cellular and infection microbiology2016
Shigella Diversity and Changing Landscape: Insights for the Twenty-First Century.
Review in Frontiers in cellular and infection microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04056117 (Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine), which is not on this map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants
Who cites it
96 citing papers in PubMed.
- Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis.BMC gastroenterology · 2021Trial
- Antibodies Elicited by theFrontiers in immunology · 2021Trial
- Review
- Global distribution and genomic characteristics ofInfectious medicine · 2026Article
- Burden of Shigella infection in children under five years living in a peri-urban area of Ouagadougou, Burkina Faso: A community-based cohort study.PLoS neglected tropical diseases · 2026Article
- Whole and Sprouted Cereals as Nutritional Modulators of the Gut Microbiota and Intestinal Inflammation in IBD.Nutrients · 2026Review
- Integrated Morphological, Functional, and Genomic Analysis of a Novel Lytic Phage (VIT_AJPSC) Infecting Multidrug-Resistant Shigella dysenteriae.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Shigella flexneri and Shigella sonnei among children under five in Kenya's urban informal settlement.Gut pathogens · 2026Article
- Bacteriophage Therapy AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Interplay between genetically predicted gut microbiota and chronic apical periodontitis: a Mendelian randomization analysis.Journal of oral microbiology · 2026Article
- Neighborhood-level socioeconomic disadvantage is associated with gut microbial composition and diversity across many chronic disease states.Frontiers in public health · 2026Article
- Identification, antimicrobial susceptibility test, and pathogenicity analysis ofFrontiers in microbiology · 2026Article
- Selenium: A Key Element in Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Neutralizing antibodies induced by IpaB and IpaC mRNA vaccines inhibitMicrobiology spectrum · 2025Article
- Can Nature Overcome Invasive Gastrointestinal Infections?International journal of molecular sciences · 2025Review
- Grazing Intensities Regulated the Effects of Seasonal Dietary Pattern on Gut Bacterial Community Composition of Sheep.Microorganisms · 2025Article
- Article
- Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.NPJ vaccines · 2024Article
- Molecular Signature of Monocytes Shaped by theInternational journal of molecular sciences · 2024Article
- Whole genome sequencing and antimicrobial resistance among clinical isolates of Shigella sonnei in Addis Ababa, Ethiopia.PloS one · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shigella is a pathovar of Escherichia coli comprising four groups, Shigella flexneri, Shigella sonnei, Shigella dysenteriae, and Shigella boydii, each of them, with the exception of S.sonnei, comprising several serotypes. Shigella accounts for the majority of dysentery causing infections occurring world-wide each year. Recent advancements in the Shigella field have led to a better understanding of the molecular mechanisms underlying host epithelial cell invasion and immune cell function manipulation, mainly using S. flexneri as a model. Host-cell invasion is the final step of the infection process, as Shigella's virulence strategy relies also on its ability to survive hostile conditions during its journey through the gastro-intestinal tract, to compete with the host microbiota and to cross the intestinal mucus layer. Hence, the diversity of the virulence strategies among the different Shigella species has not yet been deeply investigated, which might be an important step to understand the epidemiological spreading of Shigella species worldwide and a key aspect for the validation of novel vaccine candidates. The recent development of high-throughput screening and sequencing methods will facilitate these complex comparison studies. In this review we discuss several of the major avenues that the Shigella research field has taken over the past few years and hopefully gain some insights into the questions that remain surrounding this important human pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.